None listed
Conditions
Brief summary
New Zealand carry the highest age standardised global incidence of prostate cancer. New Zealand soils are also deficient in selenium levels and provide inadequate levels of selenium from diet. Therefore, this study was carried out to assess the benefits of 200µg/d selenium supplementation as selenized yeast, for six months, through changes in biomarkers known to associate with cancer. Our hypothesis was that 200µg/d selenium supplementation as selenized yeast, given for six months can modulate surrogate biomarkers associated with prostate cancer.
Interventions
Optimising selenium intake for cancer prevention - a pilot study in Auckland.
This study employed a non-randomise supplementation with 200 micrograms selenium/day for six months as selenized yeast, provided by Alltech, Ireland in a capsulated form. One capsule contained one days dosage. Supplements were provided in 2 x three month batches. Participants were informed to contact the study centre for any queries as well as reporting of any unusual event during the study protocol including side effe
Optimising selenium intake for cancer prevention - a pilot study in Auckland. This study employed a non-randomise supplementation with 200 micrograms selenium/day for six months as selenized yeast, provided by Alltech, Ireland in a capsulated form. One capsule contained one days dosage. Supplements were provided in 2 x three month batches. Participants were informed to contact the study centre for any queries as well as reporting of any unusual event during the study protocol including side effects. Participants were requested to stop supplementation if they notice any physical or emotional changes during supplementation until they check and clarify with the study centre. If significant side effects were noted, participants were requested to stop continuation of supplementation. Participants were also required to inform the study centre with regards to compliance and any noticeable side effects at the 11th week. The second batch of tablets were posted only after verifying the compliance and any side effects thus reported. Participants were to present the second compliance and noticeable side effects records at the end of the 24th week, when they visit the study centre for the post-supplementation visit. Supplements were provided to the study participants by the study coordinator Dr. Nishi Karunasinghe under the guidance of Prof. Lynnette R Ferguson (the study PI who is also a Registered nutritionist with the New Zealand Nutrition Society (Scientific research) since 2001). Supplementation took place was at individual participant's home.
Sponsors
University of Auckland
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
Male
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Caucasian males in the age range 20-80y with no known cancers except for non-melanoma skin cancers, and not taking any dietary supplements containing >50 micrograms of selenium; (inherent serum selenium <200ng/ml added after recruitment), residents within the Auckland region, willing to attend the study centre based at the Faculty of Medical and Health Sciences, University of Auckland; willing to complete study questionnaires and keeping diet and activity diaries for four consecutive days.
Exclusion criteria
Men taking any dietary supplements containing >50 micrograms of selenium. With cancers excluding non-melanoma skin cancers Men living outside Auckland region Non-Caucasians.
Outcome results
None listed